AnaptysBio Quarterly Income Statement
NASDAQ: ANABHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
AnaptysBio revenue and earnings
In the quarter ended Mar 31, 2026, AnaptysBio generated $25.6 million in revenue, down 8.0% from the same quarter a year earlier. AnaptysBio reported a net loss of $52.9 million, compared with a loss of $39.3 million a year earlier. Operating margin was -135.5%.
Diluted earnings per share came in at -$1.84.
Summary generated from market data by MetaCap's automated system. Methodology
AnaptysBio income statement (quarterly)
| Quarter (USD) | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 | Q2 20232023-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 25.56M | 108.25M | 76.32M | 22.26M | 27.77M | 43.11M | 30.02M | 10.97M | 7.18M | 9.01M | 3.32M | 3.46M |
| Revenue growth (YoY) | -7.98% | +151.08% | +154.26% | +102.93% | +286.84% | +378.77% | +804.67% | +217.08% | +422.49% | +32.27% | +156.61% | +184.54% |
| Operating Expenses | 60.19M | -137.66M | 41.62M | 48.43M | 55.31M | -128.32M | 52.77M | 51.29M | 49.38M | 51.14M | 41.05M | 43.60M |
| Research & Development | 33.99M | — | 31.41M | 37.82M | 41.18M | — | 42.21M | 42.00M | 37.04M | — | 30.88M | 32.92M |
| Operating Income | -34.64M | 245.91M | 34.70M | -26.17M | -27.54M | 171.43M | -22.76M | -40.32M | -42.20M | -42.13M | -37.73M | -40.14M |
| Other Income (Expense) | -18.21M | -20.87M | -19.59M | -12.42M | -11.75M | -16.85M | -10.09M | -6.33M | -1.74M | -80.00K | 424.00K | 298.00K |
| Pretax Income | -52.84M | 225.04M | 15.11M | -38.59M | -39.28M | 154.58M | -32.85M | -46.65M | -43.94M | -42.22M | -37.31M | -39.84M |
| Income Tax | 40.00K | 689.00K | 0 | 39.00K | 44.00K | 149.00K | 0 | 9.00K | 0 | -4.00K | 0 | — |
| Net Income | -52.88M | 49.61M | 15.11M | -38.63M | -39.33M | -21.78M | -32.85M | -46.66M | -43.94M | -42.21M | -37.31M | -39.84M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -1.84 | 1.62 | 0.54 | -1.34 | -1.28 | -0.63 | -1.14 | -1.71 | -1.64 | -1.59 | -1.41 | -1.50 |
| EPS (Diluted) | -1.84 | 1.66 | 0.52 | -1.34 | -1.28 | -0.43 | -1.14 | -1.71 | -1.64 | -1.59 | -1.41 | -1.50 |
| Shares Outstanding (Basic) | 28.69M | — | 27.83M | 28.81M | 30.64M | — | 28.89M | 27.36M | 26.80M | — | 26.55M | 26.63M |
| Shares Outstanding (Diluted) | 28.69M | — | 29.02M | 28.81M | 30.64M | — | 28.89M | 27.36M | 26.80M | — | 26.55M | 26.63M |
| EBITDA | -34.51M | 245.50M | 35.12M | -26.31M | -27.39M | 170.99M | -22.61M | -40.17M | -42.04M | -41.97M | -37.57M | -39.98M |
| Operating Margin | -135.53% | 227.17% | 45.47% | -117.55% | -99.16% | 397.63% | -75.81% | -367.52% | -587.84% | -467.91% | -1137.19% | -1160.20% |
| Net Margin | -206.93% | 45.83% | 19.80% | -173.52% | -141.62% | -50.53% | -109.44% | -425.30% | -612.01% | -468.75% | -1124.41% | -1151.59% |
This table shows 12 quarterly periods of AnaptysBio's income statement, from Q1 2026 back to Q2 2023, across 16 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow ANAB's reporting calendar. What is a income statement?